265 results match your criteria: "Atypical Small Acinar Proliferation"
Prostate Cancer Prostatic Dis
November 2024
Department of Surgery, Oncology, and Gastroenterology - Urology Clinic, University of Padua, Padua, Italy.
J Pathol Transl Med
May 2024
Department of Pathology, Kanuni Training and Research Hospital, Health Sciences University, Trabzon, Türkiye.
Zhonghua Nan Ke Xue
May 2023
Department of Urology 2nd , China-Japan Union Hospital of Jilin University, Changchun, Jilin 130032, China.
Objective: To explore the association between atypical small acinar proliferation (ASAP) and subsequent diagnosis of intermediate and high risk prostate cancer (PCa), and analyze whether delaying repeat biopsy timing is safe and effective.
Methods: From June 2000 to June 2022, we retrospectively analyzed the clinical data of 276 patients accepting prostatic biopsy and diagnosed with ASAP in China-Japan Union Hospital of Jilin University. 54.
Oncology
July 2024
Urology 2nd Department, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
J Urol
February 2024
Department of Urology, Wayne State University, Detroit, Michigan.
Purpose: We investigated the association of MRI findings in men with a previous diagnosis of atypical small acinar proliferation (ASAP) or multifocal high-grade intraepithelial neoplasia (HGPIN) with pathologic findings on repeat biopsy.
Materials And Methods: We retrospectively reviewed patients with ASAP/multifocal HGPIN undergoing a repeat biopsy in the Michigan Urological Surgery Improvement Collaborative registry. We included men with and without an MRI after the index biopsy demonstrating ASAP/multifocal HGPIN but before the repeat biopsy.
North Clin Istanb
September 2023
Department of Urology, Asklepios Klinik Triberg, Triberg, Germany.
Virchows Arch
March 2023
Pathology Laboratory, Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal.
Radiology
April 2023
From the Division of Surgery and Interventional Science (V.S., J.M.N., F.G., A.G., L.M.C.E., S.P., H.C.W., M.E.), Medical Research Council Clinical Trials Unit (L.C.B., R.S.K.), and Centre for Medical Imaging (S.P.), University College London, Charles Bell House, 43-45 Foley St, London W1W 7TS, UK; The Alan Turing Institute, London, UK (V.S., S.K.); Departments of Urology (V.S., J.M.N., A.G., M.E.), Radiology (F.G., A.K., S.P.), and Pathology (A.F., A. Haider., L.M.C.E.), University College London Hospitals NHS Foundation Trust, London, UK; Medical Research Council Biostatistics Unit, University of Cambridge, Cambridge, UK (S.K.); Computational Pathology Group, Institute of Cancer Research, Sutton, London, UK (N.T.); Department of Urology, Frimley Health NHS Foundation Trust, London, UK (S.R.J.B.); Department of Urology, Taunton & Somerset NHS Foundation Trust, Taunton, UK (N.B.C.); Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, UK (T.J.D.); Department of Radiology, Royal Free London NHS Foundation Trust, London, UK (A.E.S.B.); Department of Urology, Whittington Health NHS Trust, London, UK (M.G.); Department of Urology, Maidstone & Tunbridge Wells NHS Trust, Tunbridge Wells, UK (A. Henderson); Department of Urology, Hampshire Hospitals NHS Foundation Trust, UK (R.G.H.); Public and patient representative, Nottingham, UK (R.O.); Department of Academic Urology, The Royal Marsden NHS Foundation Trust, Sutton, UK (C.P.); Department of Urology, North Bristol NHS Trust, Bristol, UK (R.P.); Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK (D.J.R.); Department of Urology, Wrexham Maelor Hospital NHS Trust, Wrexham, UK (I.S.S.); Department of Urology, Imperial College Healthcare NHS Trust, London, UK (M.W., H.U.A.); and Imperial Prostate, Division of Surgery, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London, London, UK (M.W., H.U.A.).
Zhonghua Bing Li Xue Za Zhi
September 2022
Department of Pathology, Guangzhou Women and Children's Medical Center, Guangdong Provincial Clinical Research Center for Child Health,Guangzhou 510623, China.
Asian J Urol
January 2022
U-merge Ltd. (Urology for Emerging Countries), London, UK.
Pathogens
January 2022
Dipartimento di Scienze Biomediche, Università di Sassari, 07100 Sassari, Italy.
Zhonghua Nan Ke Xue
September 2021
Department of Urology, Zhangzhou Hospital Affiliated to Fujian Medical University, Zhangzhou, Fujian 363000, China.
Sci Rep
November 2021
Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea.
Ir J Med Sci
October 2022
Anatomic Pathology Department, Galway University Hospital, Galway, Ireland.
Background: In the era of active surveillance of low- and intermediate-risk prostatic cancer, a reconsideration of the implications of a biopsy report of ASAP and/or HGPIN may be timely.
Aims: We investigated the implications of a diagnosis of atypical small acinar proliferation (ASAP) and high-grade prostatic intraepithelial neoplasia (HGPIN) on prostate biopsy.
Methods: The rate of re-biopsy and the incidence of carcinoma on repeat biopsy for benign, HGPIN, and ASAP groups were compared.
BJU Int
May 2022
Department of Urology, Vall d´Hebron Hospital, Barcelona, Spain.
Objective: To analyse the current predictive value of isolated high-grade prostatic intraepithelial neoplasia (HGPIN) for clinically significant prostate cancer (csPCa) detection in repeat biopsies.
Patients And Methods: A cohort of 293 men with isolated HGPIN detected in previous biopsies performed without multiparametric magnetic resonance imaging (mpMRI), and who underwent repeat biopsy within 1 to 3 years, was analysed. Pre-repeat biopsy mpMRI and guided biopsies to suspicious lesions (Prostate Imaging - Reporting and Data System [PI-RADS] ≥3) and/or and systematic biopsies were performed.
Actas Urol Esp (Engl Ed)
October 2021
Departamento de Urología y Trasplante Renal, Hospital Universitario Vall d'Hebrón, Universidad Autónoma de Barcelona, Barcelona, Spain; Universidad Autónoma de Barcelona, Barcelona, Spain.
Background: Repeat prostate biopsy (PBx) is recommended under persistent suspicion of prostate cancer (PCa) or in the face of the following findings: atypical small acinar proliferation (ASAP); extense (≥3 biopsy sites) high-grade prostatic intraepithelial neoplasia (HGPIN); or HGPIN with atypical glands; suspicious for adenocarcinoma (PIN-ATYP). Nowadays; multiparametric magnetic resonance imaging (mpMRI) and mpMRI targeted PBx (MRI-TBx) are recommended in repeat PBx. Our objective was to analyze the current value of ASAP; mHGPIN; PIN-ATYP and other histological findings to predict clinically significant PCa (csPCa) risk.
View Article and Find Full Text PDFUrologia
August 2021
Department of Urology, Catholic University of the Sacred Heart - Fondazione Policlinico Universitario "A. Gemelli" - IRCSS, Rome, Italy.
Background: Atypical small acinar proliferation (ASAP) occurs in approximately 5% of prostate biopsies. Approximately 30%-40% of these patients may develop prostate cancer (PCa) within a 5-year period, often not clinically significant. Current guidelines recommend a repeat biopsy within 3-6 months after the initial diagnosis, but it seem not to be the best strategy.
View Article and Find Full Text PDFScand J Urol
April 2021
Division of Urology, Città della Salute e della Scienza - Molinette Hospital, University of Turin, Turin, Italy.
Objective: To evaluate the premalignant potential of high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar proliferation (ASAP).
Methods: Patients diagnosed with monofocal HGPIN (mHGPIN), widespread HGPIN (≥4 cores, wHGPIN) and/or ASAP who underwent at least one rebiopsy during their follow-up, were enrolled. All enrollment biopsies underwent central pathologic revision.
Lancet Digit Health
August 2020
Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Background: There is high demand to develop computer-assisted diagnostic tools to evaluate prostate core needle biopsies (CNBs), but little clinical validation and a lack of clinical deployment of such tools. We report here on a blinded clinical validation study and deployment of an artificial intelligence (AI)-based algorithm in a pathology laboratory for routine clinical use to aid prostate diagnosis.
Methods: An AI-based algorithm was developed using haematoxylin and eosin (H&E)-stained slides of prostate CNBs digitised with a Philips scanner, which were divided into training (1 357 480 image patches from 549 H&E-stained slides) and internal test (2501 H&E-stained slides) datasets.
Urol Oncol
July 2021
Department of Urology, Vall d´Hebron Hospital, Barcelona, Spain; Research group in Urology. Vall d´Hebron Research Institute; Universitat Autònoma de Barcelona, Barcelona, Spain.
Objective: To assess the current ability of atypical small acinar proliferation (ASAP), multifocal high-grade prostatic intraepithelial neoplasia (mHGPIN), HGPIN with atypia (PINATYP) and other non-malignant lesions to predict clinically significant prostate cancer (csPCa) in repeat prostate biopsies.
Methods: This retrospective study analyzed 377 repeat prostate biopsies, carried out between 2.014 and 2.
Radiography (Lond)
May 2021
Medical Physics Unit, Gemelli Molise Hospital, Campobasso, Italy. Electronic address:
Introduction: The purpose of our work was to evaluate the feasibility of prostate multiparametric MR imaging at 1.5-T without endorectal coil using an 8 channel pelvic phased array coil.
Material And Methods: A total of 154 patients who underwent mp-MRI were retrospectively included.
Exp Ther Med
December 2020
Urology Department, 'Iuliu Hatieganu' University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Atypical small acinar proliferation (ASAP) and high grade intraepithelial neoplasia (HGPIN) patterns identified at prostate biopsy yield an important clinical significance, their presence signaling an increased likelihood of future oncological development or underdiagnosed PCa. MRI and MRI-TRUS fusion prostate biopsy have recently become the standard for the diagnosis of prostate cancer. Thus, we aimed to assess the role of ASAP/HGPIN pattern in the context of these recent developments as compared with the standard systematic biopsy.
View Article and Find Full Text PDFJ Urol
March 2021
Departments of Pathology, NYU Langone Health, New York, New York.
Purpose: A benign magnetic resonance imaging targeted prostate biopsy in the setting of a PI-RADS™ 4/5 abnormality presents a clinical dilemma for future management. We evaluated benign histological features on magnetic resonance imaging targeted prostate biopsy to determine if they predict the likelihood of missed cancer on subsequent biopsy.
Materials And Methods: Between June 2012 and September 2016, 1,595 men were enrolled in a prospective study of magnetic resonance imaging targeted and systematic biopsy outcomes.
Mol Clin Oncol
December 2020
Department of Urology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyōgo 662-0918, Japan.
Current guidelines recommend a repeat biopsy within 3-6 months after an initial diagnosis of atypical small acinar proliferation (ASAP) due to the high incidence of cancer detection on repeat biopsy. The current study sought to investigate practice patterns after a diagnosis of ASAP in a real-world setting and examine the clinicopathological outcomes of repeat biopsy. The departmental database of the Hyogo Prefectural Nishinomiya Hospital identified 97 of 1,218 patients with a diagnosis of ASAP on initial biopsy from 2011 to 2016.
View Article and Find Full Text PDF